OncoMatch/Clinical Trials/NCT06932757
Adjuvant Quisinostat in High-Risk Uveal Melanoma
Is NCT06932757 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Quisinostat for uveal melanoma.
Treatment: Quisinostat — The purpose of this study is to see if giving participants quisinostat will prevent participants' uveal melanoma tumor from spreading. The researchers want to find out the effects that quisinostat has on participants' condition.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Grade: class 2 (gene expression profiling (gep; decisiondx-um))
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: definitive therapy of the primary UM — primary
Definitive therapy of the primary UM must have been completed within 183 days of initiating protocol therapy.
Cannot have received: adjuvant treatment for UM
Previous adjuvant treatment for UM after definitive primary tumor therapy.
Cannot have received: Histone Deacetylase (HDAC) inhibitor
History of prior Histone Deacetylase (HDAC) inhibitor use.
Lab requirements
Blood counts
adequate organ and marrow function as defined by the local institutional lab and treating physician
Kidney function
adequate organ and marrow function as defined by the local institutional lab and treating physician
Liver function
adequate organ and marrow function as defined by the local institutional lab and treating physician
Cardiac function
cardiac ejection fraction within normal range as defined by institutional standards; no history of clinically significant cardiac arrhythmia as determined by a cardiologist; QTcB < 480 msec; no history of long QT syndrome
Adequate organ and marrow function as defined by the local institutional lab and treating physician. A QT interval corrected for heart rate using the Bazett's formula (QTcB) ≥ 480 msec or history of long QT syndrome [excluded]. Patients with a cardiac ejection fraction outside of the normal range as defined by institutional standards or with a history of clinically significant cardiac arrhythmia as determined by a cardiologist [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify